Sofosbuvir plus ribavirin is tolerable and effective even in elderly patients 75-years-old and over

BACKGROUND: Although clinical use of sofosbuvir plus ribavirin has been approved for patients infected with genotype 2 hepatitis C virus, patients ≥ 75-years-old have not been included in previous clinical trials. AIM: To evaluate the real-world safety and efficacy of sofosbuvir plus ribavirin for e...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:World J Hepatol
Egile Nagusiak: Tamai, Hideyuki, Shingaki, Naoki, Ida, Yoshiyuki, Shimizu, Ryo, Maeshima, Shuya, Okamura, Junpei, Kawashima, Akira, Nakao, Taisei, Hara, Takeshi, Matsutani, Hiroyoshi, Nishikawa, Izumi, Higashi, Katsuhiko
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Baishideng Publishing Group Inc 2020
Gaiak:
Prospective Study
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7522558/
https://ncbi.nlm.nih.gov/pubmed/33033572
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4254/wjh.v12.i9.672
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak